ImmunoGen (IMGN) Stock Price, News & Analysis

Company Overview

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Key Stats

• Today's Range: $31.23 to $31.23
• 50-Day Range: $31.23 to $31.23
• 52-Week Range: $3.61 to $31.25
• Volume: 40 shs
• Average Volume: 8.78 million shs
• Market Capitalization: $8.32 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.04
• Consensus Rating: Hold

ImmunoGen Stock Analysis - MarketRank™

ImmunoGen scored higher than 28% of companies evaluated by MarketBeat, and ranked 808th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

ImmunoGen has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

ImmunoGen has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 362.50%

Earnings Growth

Earnings for ImmunoGen are expected to grow by 362.50% in the coming year, from $0.08 to $0.37 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ImmunoGen is -100.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ImmunoGen is -100.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ImmunoGen has a P/B Ratio of 43.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for IMGN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ImmunoGen does not currently pay a dividend.

Dividend Growth

ImmunoGen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -0.77

Short Interest

There is no current short interest data available for IMGN.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ImmunoGen insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.07% of the stock of ImmunoGen is held by insiders.

Percentage Held by Institutions

90.50% of the stock of ImmunoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IMGN Stock Analysis - Frequently Asked Questions

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) issued its earnings results on Monday, July, 31st. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.14. The company's revenue was up 485.9% compared to the same quarter last year.

Does ImmunoGen have any subsidiaries?

ImmunoGen subsidiaries include these companies: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoGen investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), General Electric (GE), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

• Last Earnings: 7/31/2023
• Today: 11/24/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMGN
• CUSIP: 45253H10
• CIK: 855654
• Web: www.immunogen.com
• Phone: (781) 895-0600
• Fax: 781-895-0611
• Employees: 277
• Year Founded: 1981

Price Target and Rating

• Average Stock Price Target: $31.04
• High Stock Price Target: $31.26
• Low Stock Price Target: $31.00
• Potential Upside/Downside: -0.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 390.38
• P/E Growth: N/A
• Net Income: $-222,930,000.00
• Net Margins: -25.56%
• Pretax Margin: -25.24%
• Return on Equity: -22.11%
• Return on Assets: -13.53%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 5.70
• Quick Ratio: 5.65

Sales & Book Value

• Annual Sales: $287.61 million
• Price / Sales: 28.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.71 per share
• Price / Book: 43.99

Miscellaneous

• Outstanding Shares: 266,264,000
• Free Float: 252,764,000
• Market Cap: $8.32 billion
• Optionable: Optionable
• Beta: 1.18